drugset
drugset / Trial / NCT01264679

A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease

NCT01264679 ↗

Phase 3 Terminated 8 enrolled AMAG Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

Study AMAG-FER-CKD-253 is an extension study of the combined AMAG-FER-CKD-251 (NCT01155375) and AMAG-FER-CKD-252 (NCT01155388) studies to evaluate the efficacy and safety of episodic treatment of iron deficiency anemia (IDA) with ferumoxytol.

Timeline

Start
2011-12-27
Primary completion
2015-04-24
Completion
2015-04-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Ferumoxytol Diagnostic / imaging agent 7 mg/kg Intravenous

Indications

iron deficiency anemia